HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Molecular and preclinical basis to inhibit PGE2 receptors EP2 and EP4 as a novel nonsteroidal therapy for endometriosis.

Abstract
Endometriosis is a debilitating, estrogen-dependent, progesterone-resistant, inflammatory gynecological disease of reproductive age women. Two major clinical symptoms of endometriosis are chronic intolerable pelvic pain and subfertility or infertility, which profoundly affect the quality of life in women. Current hormonal therapies to induce a hypoestrogenic state are unsuccessful because of undesirable side effects, reproductive health concerns, and failure to prevent recurrence of disease. There is a fundamental need to identify nonestrogen or nonsteroidal targets for the treatment of endometriosis. Peritoneal fluid concentrations of prostaglandin E2 (PGE2) are higher in women with endometriosis, and this increased PGE2 plays important role in survival and growth of endometriosis lesions. The objective of the present study was to determine the effects of pharmacological inhibition of PGE2 receptors, EP2 and EP4, on molecular and cellular aspects of the pathogenesis of endometriosis and associated clinical symptoms. Using human fluorescent endometriotic cell lines and chimeric mouse model as preclinical testing platform, our results, to our knowledge for the first time, indicate that selective inhibition of EP2/EP4: (i) decreases growth and survival of endometriosis lesions; (ii) decreases angiogenesis and innervation of endometriosis lesions; (iii) suppresses proinflammatory state of dorsal root ganglia neurons to decrease pelvic pain; (iv) decreases proinflammatory, estrogen-dominant, and progesterone-resistant molecular environment of the endometrium and endometriosis lesions; and (v) restores endometrial functional receptivity through multiple mechanisms. Our novel findings provide a molecular and preclinical basis to formulate long-term nonestrogen or nonsteroidal therapy for endometriosis.
AuthorsJoe A Arosh, JeHoon Lee, Dakshnapriya Balasubbramanian, Jone A Stanley, Charles R Long, Mary W Meagher, Kevin G Osteen, Kaylon L Bruner-Tran, Robert C Burghardt, Anna Starzinski-Powitz, Sakhila K Banu
JournalProceedings of the National Academy of Sciences of the United States of America (Proc Natl Acad Sci U S A) Vol. 112 Issue 31 Pg. 9716-21 (Aug 04 2015) ISSN: 1091-6490 [Electronic] United States
PMID26199416 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Biphenyl Compounds
  • Estrogens
  • Receptors, Prostaglandin E, EP2 Subtype
  • Receptors, Prostaglandin E, EP4 Subtype
  • Steroids
  • Xanthones
  • 6-isopropoxy-9-oxoxanthene-2-carboxylic acid
  • Progesterone
  • AH 23848
  • Poly(ADP-ribose) Polymerases
  • Caspase 3
Topics
  • Animals
  • Apoptosis (drug effects)
  • Biphenyl Compounds (pharmacology, therapeutic use)
  • Caspase 3 (metabolism)
  • Cell Line
  • Cell Movement (drug effects)
  • Cell Survival (drug effects)
  • Disease Models, Animal
  • Endometriosis (drug therapy, pathology)
  • Endometrium (blood supply, pathology)
  • Estrogens (biosynthesis)
  • Female
  • Humans
  • Inflammation (pathology)
  • Mice
  • Neovascularization, Pathologic (metabolism, pathology)
  • Pelvic Pain (drug therapy, pathology)
  • Poly(ADP-ribose) Polymerases (metabolism)
  • Progesterone (metabolism)
  • Receptors, Prostaglandin E, EP2 Subtype (antagonists & inhibitors)
  • Receptors, Prostaglandin E, EP4 Subtype (antagonists & inhibitors)
  • Signal Transduction (drug effects)
  • Steroids (therapeutic use)
  • Xanthones (pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: